Karyopharm Therapeutics Inc.
KPTI
Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases. The company discovers, develops, and commercializes novel and Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1. Its lead coā¦ read more
Healthcare
Biotechnology
12 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$6.94
Price+8.95%
$0.57
1Y
Price
Market Cap
$59.249m
Small
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financials Overview
Key metrics over the past few years-51.2%
EBITDA Margin-75.2%
Net Profit Margin-
Free Cash Flow MarginRevenue
$142.530m
-1.9%
1y CAGR-3.1%
3y CAGR-8.6%
5y CAGREarnings
-$124.621m
-63.1%
1y CAGR-1.0%
3y CAGR-9.1%
5y CAGREPS
-$14.58
-54.9%
1y CAGR+11.0%
3y CAGR+2.7%
5y CAGRBook Value
-$269.258m
$96.232m
Assets$365.490m
Liabilities$196.423m
DebtDebt to Assets
204.1%
-2.4x
Debt to EBITDAFree Cash Flow
-$83.438m
+34.6%
1y CAGR+11.7%
3y CAGR+0.6%
5y CAGRFinancial Reports
Earnings and other important metrics. Amounts in USD.No items found.
Press Releases
Statements and updates from the company